Combined treatment of heart failure after coronary heart disease

Clinical effect observation of Sacubitril/valsartan combined with Qili cardiotonic capsule on patients with heart failure after coronary heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16538701

Enrollment

106

Registered

2025-05-20

Start date

2022-12-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined treatment of heart failure after coronary heart disease Circulatory System

Interventions

106 patients with coronary heart disease and heart failure were randomly divided into control group and experimental group by simple random grouping method, 53 cases in each group.The control group wa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meeting the 2021 European Society of Cardiology diagnostic criteria and treatment guidelines for acute and chronic heart failure; 2. The heart failure classification conformed to the New York Heart Association (NYHA) cardiac function classification II-IV; 3. Chronic heart failure with coronary heart disease.

Exclusion criteria

Exclusion criteria: 1. Combined with other cardiovascular diseases leading to heart failure, such as severe valvular disease, malignant arrhythmia, acute myocarditis, acute myocardial infarction, various types of cardiomyopathy, malignant hypertension 2. Complicated with severe liver, kidney, lung or other important organ dysfunction 3. Combined with malignant tumor; severe anemia requiring blood transfusion 4. Patients who could not complete all follow-ups 5. Patients who did not test blood routine within 24 hours of hospitalization

Design outcomes

Primary

Measure	Time frame
1. N-terminal pro-brain natriuretic peptide (NT-proBNP) is measured using immunoassay at baseline and at 6 months 2. 6-minute walking distance is measured using the 6-minute walking test (6MWT) at baseline and at 6 months 3. Left ventricular ejection fraction (LVEF) is measured using echocardiography at baseline and at 6 months 4. Left ventricular end-systolic diameter (LVESD) is measured using echocardiography at baseline and at 6 months 5. Left ventricular end-diastolic diameter (LVEDD) is measured using echocardiography at baseline and at 6 months	—

Measure

Time frame

1. N-terminal pro-brain natriuretic peptide (NT-proBNP) is measured using immunoassay at baseline and at 6 months 2. 6-minute walking distance is measured using the 6-minute walking test (6MWT) at baseline and at 6 months 3. Left ventricular ejection fraction (LVEF) is measured using echocardiography at baseline and at 6 months 4. Left ventricular end-systolic diameter (LVESD) is measured using echocardiography at baseline and at 6 months 5. Left ventricular end-diastolic diameter (LVEDD) is measured using echocardiography at baseline and at 6 months

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

China

Contacts

Public ContactLan Hai

hanlan_lher@163.com+86-18193837516

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026